BJC reports最新文献

筛选

英文中文

A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors. CDK4/6抑制剂ribociclib联合吉西他滨治疗晚期实体瘤患者的I期研究

BJC reports Pub Date : 2025-01-14 DOI: 10.1038/s44276-024-00107-0

Aurora Norman, Mahesh Seetharam, Jacob Allred, Jianping Kong, Mateusz Opyrchal, Wen Wee Ma, Yanyan Lou, Grace K Dy, Amit Mahipal, S John Weroha, Andrea E Wahner Hendrickson, Joel M Reid, Alex A Adjei

{"title":"A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors.","authors":"Aurora Norman, Mahesh Seetharam, Jacob Allred, Jianping Kong, Mateusz Opyrchal, Wen Wee Ma, Yanyan Lou, Grace K Dy, Amit Mahipal, S John Weroha, Andrea E Wahner Hendrickson, Joel M Reid, Alex A Adjei","doi":"10.1038/s44276-024-00107-0","DOIUrl":"10.1038/s44276-024-00107-0","url":null,"abstract":"Background: Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine was synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT).Methods: In this single arm multicohort phase I trial, we evaluated the safety and efficacy of ribociclib plus gemcitabine in patients with advanced solid tumors. Patients received gemcitabine intravenously on days 1 and 8 followed by ribociclib days 8-14, with treatment repeated every 3 weeks.Results: The study enrolled 43 patients between October 2017 and September 2019. The escalation phase (19 patients) determined the MTD and recommended phase II dose (RP2D) to be ribociclib 800 mg daily and gemcitabine 1000 mg/m2 for the expansion phase (24 patients). One patient experienced Grade 4 thrombocytopenia. Eleven patients experienced Grade 3 adverse events (AE), the most common being neutropenia, thrombocytopenia, and anemia. No partial or complete responses were observed. 15/22 (68%) of efficacy evaluable patients who received the MTD achieved best response of stable disease.Conclusions: The addition of ribociclib to gemcitabine was tolerated well and yielded stability of tumors in both cohorts. Biomarkers such as Rb status and activity of CDK2 and CDK4/6 complexes may help to select patients who may respond better to the combination of gemcitabine and ribociclib.Clinical trial registration: NCT03237390.","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma. 血清层粘连蛋白γ - 2单体作为胰腺导管腺癌新的诊断和预后指标。

BJC reports Pub Date : 2025-01-14 DOI: 10.1038/s44276-024-00116-z

Takeshi Terashima, Kouki Nio, Naohiko Koshikawa, Makoto Ueno, Tadashi Toyama, Masaki Miyazawa, Tomoyuki Hayashi, Akihiro Seki, Hidetoshi Nakagawa, Noriho Iida, Shinya Yamada, Hajime Takatori, Tetsuro Shimakami, Toru Yoshimura, Eisaku Yoshida, Masatoshi Nakagawa, Motoharu Seiki, Taro Yamashita

{"title":"Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma.","authors":"Takeshi Terashima, Kouki Nio, Naohiko Koshikawa, Makoto Ueno, Tadashi Toyama, Masaki Miyazawa, Tomoyuki Hayashi, Akihiro Seki, Hidetoshi Nakagawa, Noriho Iida, Shinya Yamada, Hajime Takatori, Tetsuro Shimakami, Toru Yoshimura, Eisaku Yoshida, Masatoshi Nakagawa, Motoharu Seiki, Taro Yamashita","doi":"10.1038/s44276-024-00116-z","DOIUrl":"10.1038/s44276-024-00116-z","url":null,"abstract":"Background: The identification of effective diagnostic and prognostic biomarkers is critical to improving the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC). We explored the potential of serum levels of laminin γ2 monomer (LG2m) as a biomarker in PDAC.Methods: This study included two cohorts. Cohort 1 included 142 PDAC patients, 55 patients with intraductal papillary mucinous neoplasm (IPMN), and 46 healthy individuals. Cohort 2 included 518 PDAC patients. The medical records of patients were reviewed. Cut-off levels for LG2m were determined by receiver operating characteristic analysis.Results: In Cohort 1, serum LG2m levels were significantly higher in PDAC patients compared with healthy individuals (P < 0.001) and IPMN patients (P < 0.001). Comparing PDAC patients and health individuals, the optimal cut-off level of LG2m was 9.55 pg/mL and the sensitivity, specificity, and area under the curve were 0.89, 0.87, and 0.88, respectively. High sensitivity of LG2m in PDAC patients were confirmed in Cohort 2. The sensitivity and specificity of LG2m was higher than that of CEA and CA19-9. In patients treated with resection or chemotherapy, high serum LG2m level indicated a significantly shorter survival (P = 0.042 and P < 0.001, respectively).Conclusions: LG2m may be a useful diagnostic and prognostic marker for PDAC.","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页